Iovance Biotherapeutics, Inc. (IOVA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$7.74-11.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IOVA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks IOVA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Expand Amtagvi use through demand, treatment-center access, and commercial growth, while pursuing the stated 2026 revenue outlook.
Stated in 2 supplied transcript quarters. Revenue rose from $71.43 million in 2026-Q1 to $99.313 million in 2026-Q2, and management later raised full-year 2026 guidance to $410 million to $420 million. The revenue increase and guidance raise show delivery on the commercial growth focus, though full-year results are not provided.
“Significant U.S. Commercial Business Growth and Progress in Global Expansion”
“We are accelerating the adoption and commercial expansion for Amtagvi after record high demand.”
Progress registrational trials, label expansions, and next-generation TIL programs across melanoma, lung cancer, sarcomas, endometrial cancer, and other solid tumors.
Stated in 3 supplied transcript quarters. The supplied financials show revenue of $71.43 million in 2026-Q1 and $99.313 million in 2026-Q2, but do not report clinical-program financial outcomes. The priority is recurring, while the financial evidence available here does not establish substantive delivery on pipeline advancement.
Continue centralized manufacturing and operational improvement initiatives intended to lower costs, improve gross margin, and advance profitability.
Stated in 2 supplied transcript quarters. Operating income improved from -$81.043 million in 2026-Q1 to -$51.905 million in 2026-Q2, but remained negative. That is measurable operational progress alongside the recurring efficiency commitment, though profitability has not been reached in the supplied financials.
Increase the authorized treatment-center network and pursue additional country approvals to broaden commercial availability of Amtagvi.
Stated in 2 supplied transcript quarters. Revenue increased from $71.43 million in 2026-Q1 to $99.313 million in 2026-Q2, but the supplied financials do not isolate the impact of treatment-center additions or international markets. The access-expansion focus is recurring, with limited financial evidence to assess its specific contribution.
“Significant U.S. Commercial Business Growth and Progress in Global Expansion”
Use biomarker-guided patient selection in lifileucel lung cancer studies, with a planned registrational development path for selected populations.
Newly stated in 2026-Q3. The supplied financials report revenue of $99.313 million in 2026-Q2, but provide no financial measure tied to this newly described biomarker strategy. It is too early to assess delivery; the cited disclosure describes clinical rationale and planned evaluation rather than a completed financial milestone.
“The KRAS findings and further biomarker enrichment provide the clinical foundation for Iovance's precision TIL strategy.”
Over the trailing year it converted 0.90x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.
“Iovance's TIL platform spans registrational trials and next-generation programs in additional solid tumors”
“Deep Pipeline of Registrational Programs”
“advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway”
“Operational Excellence Focused on Profitability”
“Internal manufacturing efficiencies, operational improvements, and cost reductions will benefit gross margin”
“Amtagvi global expansion is advancing”